- ￥6768
- AntibodySystem
- 93.75 - 1,500 ng/mL
- 47.39 ng/mL
- KDJ41001
- France
- 2025年07月12日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 库存：
999
- 供应商：
AntibodySystem
- 检测范围：
93.75 - 1,500 ng/mL
- 检测方法：
Colorimetric
- 应用：
Used for the quantitative determination of Enfortumab concentration in serum and plasma.
- 标记物：
HRP
- 样本：
Plasma, Serum
- 灵敏度：
47.39 ng/mL
- 规格：
96T
| 描述 | PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human NECTIN4 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Enfortumab in the sample competitively binds to the pre-coated protein with biotin-labeled Enfortumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Enfortumab bound in the initial step. The color development is stopped and the intensity of the color is measured. | ||||||||||||||||||||||||||||||||||||||||||
| 应用 | Used for the quantitative determination of Enfortumab concentration in serum and plasma. | ||||||||||||||||||||||||||||||||||||||||||
| 稳定性和存储 | When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃. | ||||||||||||||||||||||||||||||||||||||||||
| 检测方法 | Colorimetric | ||||||||||||||||||||||||||||||||||||||||||
| 精准度 |
Intra-Assay Precision (Precision within an assay): <20% Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision. Inter-Assay Precision (Precision between assays): <20% Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
| ||||||||||||||||||||||||||||||||||||||||||
| 样本类型 | Plasma, Serum | ||||||||||||||||||||||||||||||||||||||||||
| 实验类型 | Quantitative | ||||||||||||||||||||||||||||||||||||||||||
| 灵敏度 | 47.39 ng/mL | ||||||||||||||||||||||||||||||||||||||||||
| 检测范围 | 93.75 - 1,500 ng/mL | ||||||||||||||||||||||||||||||||||||||||||
| 回收率 | 80-120% | ||||||||||||||||||||||||||||||||||||||||||
| 背景 | Enfortumab vedotin is an antibody-drug conjugate (ADC) designed for the treatment of cancer expressing Nectin-4. It was developed through two main lines, hybridoma (ASG-22ME) and Chinese hamster ovary (ASG-22CE). Enfortumab refers to the fully humanized (from mouse) monoclonal antibody (mAb) created by scientists at Agensys (part of Astellas) using Amgen’s transgenic system (XenoMouse), it is the first agent to target Nectin-4 that expressed on many solid tumors especially on bladder cancers. Vedotin refers to the payload drug microtubule-disrupting agent monomethyl auristatin E (MMAE) and the linker. The linker technology holding the antibody and the toxin together was provided by and licensed from Seattle Genetics. Preclinical studies showed that enfortumab vedotin effectively binds to target cells, internalizes and induces cell-killing activity. Mouse and patient xenograft models were used to test enfortumab vedotin’s antitumor activity in human breast, bladder, pancreatic and lung cancers. In March 2018, Seattle Genetics and Astellas received the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for enfortumab vedotin based on interim results from the phase 1 study examining enfortumab vedotin as monotherapy treatment for patients with metastatic urothelial cancer who were previously treated with checkpoint inhibitors. | ||||||||||||||||||||||||||||||||||||||||||
| 别名 | AGS-22CE, AGS-22M, AGS-22M6E, unconjugated : AGS-22C3 or AGSM6, CAS: 1346452-25-2 | ||||||||||||||||||||||||||||||||||||||||||
| 运输 | 2-8 ℃ | ||||||||||||||||||||||||||||||||||||||||||
| 备注 | For Research Use Only. | ||||||||||||||||||||||||||||||||||||||||||
AntibodySystem Laboratories SAS was established in 2019 in France as an independent brand entity focused on the research, development, and production of protein and antibody reagents in the life sciences field. Our mission is to provide high-quality protein and antibody products to life science researchers worldwide. AntibodySystem's extensive product range includes traditional polyclonal antibodies, classic housekeeping antibodies, tag antibodies, high-activity proteins, in vivo functional antibodies, low-background flow cytometry antibodies, high-specificity nanobodies, specialized small molecule antibodies, premium phospho-specific antibodies, DNA/RNA antibodies, PEG antibodies, and more—spanning over ten product series.
Currently, AntibodySystem's product lines cover multiple research areas, including 48 types of viruses and superbugs, parasites, tumors, Alzheimer's disease, Parkinson's disease, hypersensitivity and allergic reactions, immune suppression, and immune activation.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
